Abstract:Colorectal cancer (CRC) is among the most widely spread cancers globally. Aberrant alternative polyadenylation (APA) plays a role in cancer onset and its progression. Consequently, this study focused on highlighting the role of APA events and signals in the prognosis of patients with CRC. The APA events, RNA sequencing (RNA-seq), somatic mutations, copy number variants (CNVs), and clinical information of the CRC cohort were obtained from The Cancer Genome Atlas (TCGA) database and UCSC (University of California-Santa Cruz) Xena database. The whole set was sorted into two sets: a training set and a test set in a ratio of 7:3. 197 prognosis-related APA events were collected by performing univariate Cox regression signature in patients with CRC. Subsequently, a signature for APA events was established by least absolute shrinkage and selection operator (LASSO) and multivariate Cox analysis. The risk scores were measured for individual patients on the basis of the signature and patients were sorted into two groups; the high-risk group and the low-risk group as per their median risk scores. Kaplan-Meier curves, principal component analysis (PCA), and time-dependent receiver operator characteristic (ROC) curves revealed that the signature was able to predict patient prognosis effectively and further validation was provided in the test set and the whole set. The high-risk and low-risk groups displayed various distributions of mutations and CNVs. Tumor mutation burden (TMB) alone and in combination with the signature predicted the prognosis of CRC patients, but the gene frequencies of TMBs and CNVs did not change in the low- and high-risk groups. Moreover, immunotherapy and chemotherapy treatments showed different responses to PD-1 inhibitors and multiple chemotherapeutic agents in the low and high-risk groups based on the tumor immune dysfunction and exclusion (TIDE) and genomics of drugs sensitivity in cancer (GDSC) databases. This study may help in understanding the potential roles of APA in CRC, and the signature for prognosis-related APA events can work as a potential predictor for survival and treatment in patients with CRC.

Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression

Alternative polyadenylation shapes the molecular and clinical features of lung adenocarcinoma

The role of alternative polyadenylation in epithelial-mesenchymal transition of non-small cell lung cancer

Integrated RNA expression and alternative polyadenylation analysis identified CPSF1‐CCDC137 oncogenic axis in lung adenocarcinoma

Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma

Alternative Polyadenylation Modification Patterns Reveal Essential Posttranscription Regulatory Mechanisms of Tumorigenesis in Multiple Tumor Types.

Alternative polyadenylation of single cells delineates cell types and serves as a prognostic marker in early stage breast cancer

Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer

Alternative Polyadenylation Associated with Prognosis and Therapy in Colorectal Cancer.

Cleavage and Polyadenylation Specific Factor 1 Promotes Tumor Progression via Alternative Polyadenylation and Splicing in Hepatocellular Carcinoma

Cell Cycle Regulation by Alternative Polyadenylation of CCND1.

Large-scale alternative polyadenylation-wide association studies to identify putative cancer susceptibility genes

Genome-wide Profiling of Polyadenylation Sites Reveals a Link Between Selective Polyadenylation and Cancer Metastasis

Genetic variants that impact alternative polyadenylation in cancer represent candidate causal risk loci

Comprehensive Analysis of Alternative Polyadenylation Events Associated with the Tumor Immune Microenvironment in Colon Adenocarcinoma

CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression

Alternative Polyadenylation of Mrna and Its Role in Cancer

LINC00921 reduces lung cancer radiosensitivity by destabilizing NUDT21 and driving aberrant MED23 alternative polyadenylation

APEX1 regulates alternative splicing of key tumorigenesis genes in non-small-cell lung cancer

Multiplexed screening reveals how cancer-specific alternative polyadenylation shapes tumor growth in vivo

Disruption of PABPN1 phase separation by SNRPD2 drives colorectal cancer cell proliferation and migration through promoting alternative polyadenylation of CTNNBIP1